# Entrada Therapeutics (TRDA) — Analyst Forecast

TRDA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/trda/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 6 | 1 | 0 | 7 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Jun 8, 2026 | Guggenheim | Maintained | Buy | $17.00 |
| May 8, 2026 | HC Wainwright & Co. | Downgraded | Buy → Neutral | — |
| Apr 6, 2026 | Oppenheimer | Maintained | Outperform | $23.00 |
| Feb 18, 2026 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Feb 11, 2026 | Guggenheim | Initiated Coverage | Buy | $20.00 |
| May 20, 2025 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Feb 25, 2025 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Feb 4, 2025 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Dec 5, 2024 | Roth MKM | Initiated Coverage | Buy | $29.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Nov 6, 2024 | Oppenheimer | Maintained | Outperform | $28.00 |
| Aug 26, 2024 | Oppenheimer | Maintained | Outperform | $25.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Maintained | Buy | $18.00 |
| Jun 25, 2024 | HC Wainwright & Co. | Maintained | Buy | $18.00 |
| Mar 18, 2024 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Jan 5, 2024 | Oppenheimer | Initiated Coverage | Outperform | $22.00 |
| Nov 27, 2023 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Sep 22, 2023 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Aug 9, 2023 | HC Wainwright & Co. | Maintained | Buy | $25.00 |

## Frequently Asked Questions

### Is TRDA a buy, sell, or hold?

Analysts covering Entrada Therapeutics currently average a Buy rating: 6 buy, 1 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on TRDA?

On Jun 8, 2026, Guggenheim maintained Entrada Therapeutics at Buy with a price target of $17.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).